PredictImmune grabs £10m to turbo‑charge its IBD forecasting toolkit
Why this news matters
PredictImmune – the Cambridge‑based pup that’s turning 10 years of research into life‑saving tests – just secured a £10m funding package. This cash is set to help the company take its tools from the University labs all the way to doctors’ desks around the world.
Who’re the backers?
- BGF (the UK & Ireland investor with a knack for growth) – £4m of fresh growth capital.
- Cambridge Innovation Capital (CIC) – joining the round.
- Existing investors – a proud group already rooting for the venture.
From university to clinic: the story
Founded in May 2017 at the Babraham Research Campus, PredictImmune sprang from a decade of Cambridge University research. The firm has built prognostic test kits which let doctors and patients see, right at diagnosis, how Crohn’s and ulcerative colitis (IBD) might behave. Knowing the likely course early means treatment can be personalised and smarter from day one.
What the new cash will power
- International commercialisation – spreading the tools across the UK, Europe, the US and beyond.
- Expansion of the product pipeline – adding complementary prognostic tests to enrich the offering over the next few years.
Word from the execs
Paul Kinnon, CEO: “I’m thrilled with the amount of investment we’ve snagged. It’s a huge win to see our early investors sticking with us, plus the fresh support from BGF and CIC. This money will keep our momentum alive, letting us grow across continents while continuing to innovate our product line.”
Tim Rea, BGF investor & soon‑to‑join board member: “PredictImmune’s approach to predicting disease progression is fantastic. The team has turned a decade of academic science into a real‑world tool that will change patient lives. BGF’s focus on diagnostics this year reflects our belief that breakthroughs here unlock better detection, monitoring and personalized care worldwide.”
Looking ahead
With this boost, PredictImmune is geared to carry its pioneering IBD tests far beyond the UK, tapping into a booming global demand for smarter diagnostic solutions. The company’s mission? Make it easy for doctors and patients to pick the best treatment right from the start.
Stay tuned
If you want to catch the next chapters in PredictImmune’s journey, sign up for real‑time updates and never miss a beat.
